ArticleBMC chemistry2025
Trifluoromethyl-pyrazole-carboxamides as COX inhibitors: synthesis, microed structural analysis, computational profiling, and biological evaluation.
Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Piperazine-Thiourea Hybrids as Novel Antiplatelet Agents Targeting COX-1: Synthesis,ACS omega · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely prescribed medications for the treatment of inflammation, pain, and fever, primarily acting as competitive inhibitors of the cyclooxygenase (COX) enzymes.
objectivesThe present study aimed to design a series of trifluoromethyl-pyrazole-carboxamide derivatives as potential NSAID candidates, with a focus on achieving selective COX-2 inhibition and reduced cytotoxicity. In addition, their potential anticancer effects and pharmacokinetic properties were evaluated through in vitro and in silico analyses.
methodsThe coupling reaction of aniline derivatives and pyrazole-carboxylic acid was used to synthesize a series of trifluoromethyl-pyrazole-carboxamide derivatives. Initially, the newly synthesized compounds were characterized using FTIR, HRMS,
resultsBased on the biological evaluation, compound 3b exhibited the most potent inhibitory activity against the COX-1 enzyme, with an IC₅₀ value of 0.46 µM. Additionally, it demonstrated notable COX-2 inhibitory activity, with an IC₅₀ value of 3.82 µM. In contrast, compound 3g showed the highest selectivity ratio for COX-2 (1.68), alongside potent COX-2 inhibition (IC₅₀ = 2.65 µM), outperforming the reference drug ketoprofen, which displayed a selectivity ratio of 0.21 and an IC₅₀ value against COX-2 of 0.164 µM. Furthermore, compound 3d exhibited strong COX-2 selectivity (selectivity ratio = 1.14) with an IC₅₀ value of 4.92 µM. All synthesized compounds demonstrated negligible cytotoxic effects against the tested normal cell lines. However, compound 3a exhibited cytotoxic activity against CaCo-2, MCF-7, Hep3B and HepG2 cancer cell lines with IC
conclusionCompounds 3b, 3d, and 3g demonstrated potent COX inhibition with notable COX-2 selectivity, supporting their promise as leads for safer anti-inflammatory drug development. Additionally, compound 3a displayed moderate cytotoxic effects against several cancer cell lines, suggesting possible dual anti-inflammatory and anticancer potential. Overall, the favorable drug-like properties and low toxicity profiles justify further preclinical investigation of these pyrazole-carboxamide derivatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.